We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

GSK Seeks Dismissal Of 27 Zofran Birth Defect MDL Cases Involving Generics

Mealey's (October 17, 2016, 1:00 PM EDT) -- BOSTON — GlaxoSmithKline LLC (GSK) on Oct. 13 asked the Zofran birth defect multidistrict litigation court to dismiss 27 cases in which plaintiffs allege injuries from taking one of the drug’s generic versions (In Re:  Zofran [Ondansetron] Products Liability Litigation, MDL Docket No. 2657, No. 15-md-2657, D. Mass.).

(Brief available.  Document #28-161020-008B.)

Zofran brand ondansetron is approved to treat nausea and vomiting in patients after surgery or after cancer chemotherapy.  Plaintiffs allege that GSK promoted Zofran to treat morning sickness from pregnancy and that the drug...
To view the full article, register now.